IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Heterogeneity of Human γδ T Cells and Their Role in Cancer Immunity

  • Hye Won Lee (Department of Hospital Medicine, Yonsei University College of Medicine) ;
  • Yun Shin Chung (Department of Immunology, Sungkyunkwan University School of Medicine) ;
  • Tae Jin Kim (Department of Immunology, Sungkyunkwan University School of Medicine)
  • Received : 2019.12.25
  • Accepted : 2020.02.08
  • Published : 2020.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

The γδ T cells are unconventional lymphocytes that function in both innate and adaptive immune responses against various intracellular and infectious stresses. The γδ T cells can be exploited as cancer-killing effector cells since γδ TCRs recognize MHC-like molecules and growth factor receptors that are upregulated in cancer cells, and γδ T cells can differentiate into cytotoxic effector cells. However, γδ T cells may also promote tumor progression by secreting IL-17 or other cytokines. Therefore, it is essential to understand how the differentiation and homeostasis of γδ T cells are regulated and whether distinct γδ T cell subsets have different functions. Human γδ T cells are classified into Vδ2 and non-Vδ2 γδ T cells. The majority of Vδ2 γδ T cells are Vγ9δ2 T cells that recognize pyrophosphorylated isoprenoids generated by the dysregulated mevalonate pathway. In contrast, Vδ1 T cells expand from initially diverse TCR repertoire in patients with infectious diseases and cancers. The ligands of Vδ1 T cells are diverse and include the growth factor receptors such as endothelial protein C receptor. Both Vδ1 and Vδ2 γδ T cells are implicated to have immunotherapeutic potentials for cancers, but the detailed elucidation of the distinct characteristics of 2 populations will be required to enhance the immunotherapeutic potential of γδ T cells. Here, we summarize recent progress regarding cancer immunology of human γδ T cells, including their development, heterogeneity, and plasticity, the putative mechanisms underlying ligand recognition and activation, and their dual effects on tumor progression in the tumor microenvironment.

Keywords

Acknowledgement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. NRF-2019R1A2C2006717 and NRF-2017R1A6A3A11034402).

References

  1. Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol 2013;13:88-100. https://doi.org/10.1038/nri3384
  2. Adams EJ, Gu S, Luoma AM. Human gamma delta T cells: evolution and ligand recognition. Cell Immunol 2015;296:31-40. https://doi.org/10.1016/j.cellimm.2015.04.008
  3. Chien YH, Meyer C, Bonneville M. γδ T cells: first line of defense and beyond. Annu Rev Immunol 2014;32:121-155. https://doi.org/10.1146/annurev-immunol-032713-120216
  4. Stolk D, van der Vliet HJ, de Gruijl TD, van Kooyk Y, Exley MA. Positive & negative roles of innate effector cells in controlling cancer progression. Front Immunol 2018;9:1990.
  5. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001;294:605-609. https://doi.org/10.1126/science.1063916
  6. Mishra R, Chen AT, Welsh RM, Szomolanyi-Tsuda E. NK cells and gammadelta T cells mediate resistance to polyomavirus-induced tumors. PLoS Pathog 2010;6:e1000924.
  7. Zhao Y, Niu C, Cui J. Gamma-delta (γδ) T cells: friend or foe in cancer development? J Transl Med 2018;16:3.
  8. Barrow AD, Martin CJ, Colonna M. The natural cytotoxicity receptors in health and disease. Front Immunol 2019;10:909.
  9. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, Kabelitz D, Wesch D. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol 2007;66:320-328. https://doi.org/10.1111/j.1365-3083.2007.01963.x
  10. Braza MS, Klein B. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside. Br J Haematol 2013;160:123-132. https://doi.org/10.1111/bjh.12090
  11. Hannani D, Ma Y, Yamazaki T, Dechanet-Merville J, Kroemer G, Zitvogel L. Harnessing γδ T cells in anticancer immunotherapy. Trends Immunol 2012;33:199-206. https://doi.org/10.1016/j.it.2012.01.006
  12. Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, Becker J, Schmidt-Wolf IG, Einsele H, Wilhelm M. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother 2012;35:205-213. https://doi.org/10.1097/CJI.0b013e318245bb1e
  13. Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011;105:778-786. https://doi.org/10.1038/bjc.2011.293
  14. Rei M, Pennington DJ, Silva-Santos B. The emerging protumor role of γδ T lymphocytes: implications for cancer immunotherapy. Cancer Res 2015;75:798-802. https://doi.org/10.1158/0008-5472.CAN-14-3228
  15. Fournie JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F, Ysebaert L, Laurent G. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol 2013;10:35-41. https://doi.org/10.1038/cmi.2012.39
  16. Lo Presti E, Pizzolato G, Gulotta E, Cocorullo G, Gulotta G, Dieli F, Meraviglia S. Current advances in γδ T cell-based tumor immunotherapy. Front Immunol 2017;8:1401.
  17. Xiang Z, Tu W. Dual face of Vγ9Vδ2-T cells in tumor immunology: anti- versus pro-tumoral activities. Front Immunol 2017;8:1041.
  18. Turchinovich G, Pennington DJ. T cell receptor signalling in γδ cell development: strength isn't everything. Trends Immunol 2011;32:567-573. https://doi.org/10.1016/j.it.2011.09.005
  19. Baker JE, Cado D, Raulet DH. Developmentally programmed rearrangement of T cell receptor Vgamma genes is controlled by sequences immediately upstream of the Vgamma genes. Immunity 1998;9:159-168. https://doi.org/10.1016/S1074-7613(00)80598-1
  20. Chodaczek G, Papanna V, Zal MA, Zal T. Body-barrier surveillance by epidermal γδ TCRs. Nat Immunol 2012;13:272-282. https://doi.org/10.1038/ni.2240
  21. Boyden LM, Lewis JM, Barbee SD, Bas A, Girardi M, Hayday AC, Tigelaar RE, Lifton RP. Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal gammadelta T cells. Nat Genet 2008;40:656-662. https://doi.org/10.1038/ng.108
  22. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010;10:467-478. https://doi.org/10.1038/nri2781
  23. O'Brien RL, Born WK. Gammadelta T cell subsets: a link between TCR and function? Semin Immunol 2010;22:193-198. https://doi.org/10.1016/j.smim.2010.03.006
  24. Vermijlen D, Prinz I. Ontogeny of innate T lymphocytes - some innate lymphocytes are more innate than others. Front Immunol 2014;5:486.
  25. Lanier LL, Weiss A. Presence of Ti (WT31) negative T lymphocytes in normal blood and thymus. Nature 1986;324:268-270. https://doi.org/10.1038/324268a0
  26. Morita CT, Parker CM, Brenner MB, Band H. TCR usage and functional capabilities of human gamma delta T cells at birth. J Immunol 1994;153:3979-3988. https://doi.org/10.4049/jimmunol.153.9.3979
  27. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, Van Rysselberge M, Twite N, Goldman M, Marchant A, Willems F. Human cytomegalovirus elicits fetal gammadelta T cell responses in utero. J Exp Med 2010;207:807-821. https://doi.org/10.1084/jem.20090348
  28. Parker CM, Groh V, Band H, Porcelli SA, Morita C, Fabbi M, Glass D, Strominger JL, Brenner MB. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med 1990;171:1597-1612. https://doi.org/10.1084/jem.171.5.1597
  29. Cairo C, Mancino G, Cappelli G, Pauza CD, Galli E, Brunetti E, Colizzi V. Vdelta2 T-lymphocyte responses in cord blood samples from Italy and Cote d'Ivoire. Immunology 2008;124:380-387. https://doi.org/10.1111/j.1365-2567.2007.02784.x
  30. Moens E, Brouwer M, Dimova T, Goldman M, Willems F, Vermijlen D. IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17. J Leukoc Biol 2011;89:743-752. https://doi.org/10.1189/jlb.0910501
  31. De Rosa SC, Andrus JP, Perfetto SP, Mantovani JJ, Herzenberg LA, Herzenberg LA, Roederer M. Ontogeny of gamma delta T cells in humans. J Immunol 2004;172:1637-1645. https://doi.org/10.4049/jimmunol.172.3.1637
  32. Cruz MS, Diamond A, Russell A, Jameson JM. Human αβ and γδ T cells in skin immunity and disease. Front Immunol 2018;9:1304.
  33. Allison TJ, Winter CC, Fournie JJ, Bonneville M, Garboczi DN. Structure of a human gammadelta T-cell antigen receptor. Nature 2001;411:820-824. https://doi.org/10.1038/35081115
  34. Legut M, Cole DK, Sewell AK. The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy. Cell Mol Immunol 2015;12:656-668. https://doi.org/10.1038/cmi.2015.28
  35. Davey MS, Willcox CR, Baker AT, Hunter S, Willcox BE. Recasting human Vδ1 lymphocytes in an adaptive role. Trends Immunol 2018;39:446-459. https://doi.org/10.1016/j.it.2018.03.003
  36. Pizzolato G, Kaminski H, Tosolini M, Franchini DM, Pont F, Martins F, Valle C, Labourdette D, Cadot S, Quillet-Mary A, et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proc Natl Acad Sci U S A 2019;116:11906-11915. https://doi.org/10.1073/pnas.1818488116
  37. Kazen AR, Adams EJ. Evolution of the V, D, and J gene segments used in the primate gammadelta T-cell receptor reveals a dichotomy of conservation and diversity. Proc Natl Acad Sci U S A 2011;108:E332-E340. https://doi.org/10.1073/pnas.1105105108
  38. Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, Beddoe T, Theodossis A, Williams NK, Gostick E, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol 2013;14:908-916. https://doi.org/10.1038/ni.2665
  39. Simoes AE, Di Lorenzo B, Silva-Santos B. Molecular determinants of target cell recognition by human γδ T cells. Front Immunol 2018;9:929.
  40. Hayes SM, Love PE. Stoichiometry of the murine gammadelta T cell receptor. J Exp Med 2006;203:47-52. https://doi.org/10.1084/jem.20051886
  41. Malissen M, Gillet A, Ardouin L, Bouvier G, Trucy J, Ferrier P, Vivier E, Malissen B. Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene. EMBO J 1995;14:4641-4653. https://doi.org/10.1002/j.1460-2075.1995.tb00146.x
  42. Dave VP, Cao Z, Browne C, Alarcon B, Fernandez-Miguel G, Lafaille J, de la Hera A, Tonegawa S, Kappes DJ. CD3 delta deficiency arrests development of the alpha beta but not the gamma delta T cell lineage. EMBO J 1997;16:1360-1370. https://doi.org/10.1093/emboj/16.6.1360
  43. Haks MC, Krimpenfort P, Borst J, Kruisbeek AM. The CD3gamma chain is essential for development of both the TCRalphabeta and TCRgammadelta lineages. EMBO J 1998;17:1871-1882. https://doi.org/10.1093/emboj/17.7.1871
  44. Hayes SM, Love PE. Distinct structure and signaling potential of the gamma delta TCR complex. Immunity 2002;16:827-838. https://doi.org/10.1016/S1074-7613(02)00320-5
  45. Siegers GM, Swamy M, Fernandez-Malave E, Minguet S, Rathmann S, Guardo AC, Perez-Flores V, Regueiro JR, Alarcon B, Fisch P, et al. Different composition of the human and the mouse gammadelta T cell receptor explains different phenotypes of CD3gamma and CD3delta immunodeficiencies. J Exp Med 2007;204:2537-2544. https://doi.org/10.1084/jem.20070782
  46. Recio MJ, Moreno-Pelayo MA, Kilic SS, Guardo AC, Sanal O, Allende LM, Perez-Flores V, Mencia A, Modamio-Hoybjor S, Seoane E, et al. Differential biological role of CD3 chains revealed by human immunodeficiencies. J Immunol 2007;178:2556-2564. https://doi.org/10.4049/jimmunol.178.4.2556
  47. Jensen KD, Su X, Shin S, Li L, Youssef S, Yamasaki S, Steinman L, Saito T, Locksley RM, Davis MM, et al. Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma. Immunity 2008;29:90-100. https://doi.org/10.1016/j.immuni.2008.04.022
  48. Taghon T, Yui MA, Pant R, Diamond RA, Rothenberg EV. Developmental and molecular characterization of emerging beta- and gammadelta-selected pre-T cells in the adult mouse thymus. Immunity 2006;24:53-64. https://doi.org/10.1016/j.immuni.2005.11.012
  49. Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, Bonnefoy N. Plasticity of γδ T cells: impact on the anti-tumor response. Front Immunol 2014;5:622.
  50. Hayday A, Tigelaar R. Casting new light on the TCR. Nat Immunol 2012;13:209-211. https://doi.org/10.1038/ni.2243
  51. Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013;13:133-144. https://doi.org/10.1038/nri3370
  52. Wensveen FM, Jelencic V, Polic B. NKG2D: a master regulator of immune cell responsiveness. Front Immunol 2018;9:441.
  53. Ribot JC, debarros A, Silva-Santos B. Searching for "signal 2": costimulation requirements of γδ T cells. Cell Mol Life Sci 2011;68:2345-2355. https://doi.org/10.1007/s00018-011-0698-2
  54. Testi R, Lanier LL. Functional expression of CD28 on T cell antigen receptor gamma/delta-bearing T lymphocytes. Eur J Immunol 1989;19:185-188. https://doi.org/10.1002/eji.1830190129
  55. Penninger JM, Timms E, Shahinian A, Jezo-Bremond A, Nishina H, Ionescu J, Hedrick SM, Mak TW. Alloreactive gamma delta thymocytes utilize distinct costimulatory signals from peripheral T cells. J Immunol 1995;155:3847-3855. https://doi.org/10.4049/jimmunol.155.8.3847
  56. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RA. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997;186:1407-1418. https://doi.org/10.1084/jem.186.9.1407
  57. De Rosa SC, Mitra DK, Watanabe N, Herzenberg LA, Herzenberg LA, Roederer M. Vdelta1 and Vdelta2 gammadelta T cells express distinct surface markers and might be developmentally distinct lineages. J Leukoc Biol 2001;70:518-526. https://doi.org/10.1189/jlb.70.4.518
  58. Seelige R, Searles S, Bui JD. Mechanisms regulating immune surveillance of cellular stress in cancer. Cell Mol Life Sci 2018;75:225-240. https://doi.org/10.1007/s00018-017-2597-7
  59. Bassani B, Baci D, Gallazzi M, Poggi A, Bruno A, Mortara L. Natural killer cells as key players of tumor progression and angiogenesis: old and novel tools to divert their pro-tumor activities into potent antitumor effects. Cancers (Basel) 2019;11:461.
  60. O'Donnell JS, Teng MW, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 2019;16:151-167. https://doi.org/10.1038/s41571-018-0142-8
  61. Runa F, Hamalian S, Meade K, Shisgal P, Gray PC, Kelber JA. Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biol Rep 2017;3:218-229. https://doi.org/10.1007/s40610-017-0073-7
  62. Nakamura K, Smyth MJ. Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol 2017;95:325-332. https://doi.org/10.1038/icb.2016.126
  63. Lo Presti E, Di Mitri R, Pizzolato G, Mocciaro F, Dieli F, Meraviglia S. γδ cells and tumor microenvironment: a helpful or a dangerous liason? J Leukoc Biol 2018;103:485-492. https://doi.org/10.1002/JLB.5MR0717-275RR
  64. Paul S, Lal G. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer. Int J Cancer 2016;139:976-985. https://doi.org/10.1002/ijc.30109
  65. Silva-Santos B, Serre K, Norell H. γδ T cells in cancer. Nat Rev Immunol 2015;15:683-691. https://doi.org/10.1038/nri3904
  66. Lee M, Park C, Woo J, Kim J, Kho I, Nam DH, Park WY, Kim YS, Kong DS, Lee HW, et al. Preferential infiltration of unique Vγ9Jγ2-Vδ2 T cells into glioblastoma multiforme. Front Immunol 2019;10:555.
  67. Cordova A, Toia F, La Mendola C, Orlando V, Meraviglia S, Rinaldi G, Todaro M, Cicero G, Zichichi L, Donni PL, et al. Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas. PLoS One 2012;7:e49878.
  68. Deniger DC, Moyes JS, Cooper LJ. Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol 2014;5:636.
  69. Davey MS, Willcox CR, Joyce SP, Ladell K, Kasatskaya SA, McLaren JE, Hunter S, Salim M, Mohammed F, Price DA, et al. Clonal selection in the human Vδ1 T cell repertoire indicates γδ TCR-dependent adaptive immune surveillance. Nat Commun 2017;8:14760.
  70. Sandstrom A, Peigne CM, Leger A, Crooks JE, Konczak F, Gesnel MC, Breathnach R, Bonneville M, Scotet E, Adams EJ. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity 2014;40:490-500. https://doi.org/10.1016/j.immuni.2014.03.003
  71. Yang Y, Li L, Yuan L, Zhou X, Duan J, Xiao H, Cai N, Han S, Ma X, Liu W, et al. A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen-mediated Vγ9Vδ2 T cell activation. Immunity 2019;50:1043-1053.e5. https://doi.org/10.1016/j.immuni.2019.02.016
  72. Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, Cleven A, Cheneau C, van Noorden M, Peigne CM, et al. RhoB mediates phosphoantigen recognition by Vγ9Vδ2 T cell receptor. Cell Reports 2016;15:1973-1985. https://doi.org/10.1016/j.celrep.2016.04.081
  73. Rigau M, Ostrouska S, Fulford TS, Johnson DN, Woods K, Ruan Z, McWilliam HE, Hudson C, Tutuka C, Wheatley AK, et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. Science 2020;367:eaay5516.
  74. Dai Y, Chen H, Mo C, Cui L, He W. Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human γδ T cells to induce innate anti-tumor/virus immunity. J Biol Chem 2012;287:16812-16819. https://doi.org/10.1074/jbc.M111.327650
  75. Tyler CJ, Doherty DG, Moser B, Eberl M. Human Vγ9/Vδ2 T cells: innate adaptors of the immune system. Cell Immunol 2015;296:10-21. https://doi.org/10.1016/j.cellimm.2015.01.008
  76. Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT, Patel O, Beddoe T, Gras S, Rossjohn J, et al. CD1d-lipid antigen recognition by the γδ TCR. Nat Immunol 2013;14:1137-1145. https://doi.org/10.1038/ni.2713
  77. Wu D, Wu P, Qiu F, Wei Q, Huang J. Human γδT-cell subsets and their involvement in tumor immunity. Cell Mol Immunol 2017;14:245-253. https://doi.org/10.1038/cmi.2016.55
  78. Le Nours J, Gherardin NA, Ramarathinam SH, Awad W, Wiede F, Gully BS, Khandokar Y, Praveena T, Wubben JM, Sandow JJ, et al. A class of γδ T cell receptors recognize the underside of the antigen-presenting molecule MR1. Science 2019;366:1522-1527. https://doi.org/10.1126/science.aav3900
  79. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol 2013;4:69.
  80. Almeida AR, Correia DV, Fernandes-Platzgummer A, da Silva CL, da Silva MG, Anjos DR, Silva-Santos B. Delta one t cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion/differentiation and preclinical proof of concept. Clin Cancer Res 2016;22:5795-5804. https://doi.org/10.1158/1078-0432.CCR-16-0597
  81. Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, Silberzahn T, Moreau JF, Hayday AC, Willcox BE, Dechanet-Merville J. Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat Immunol 2012;13:872-879. https://doi.org/10.1038/ni.2394
  82. Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 2014;20:5708-5719. https://doi.org/10.1158/1078-0432.CCR-13-3451
  83. Li Z, Xu Q, Peng H, Cheng R, Sun Z, Ye Z. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway. Int Immunopharmacol 2011;11:496-503. https://doi.org/10.1016/j.intimp.2011.01.001
  84. Tawfik D, Groth C, Gundlach JP, Peipp M, Kabelitz D, Becker T, Oberg HH, Trauzold A, Wesch D. TRAIL-receptor 4 modulates γδ T cell-cytotoxicity toward cancer cells. Front Immunol 2019;10:2044.
  85. Pauza CD, Liou ML, Lahusen T, Xiao L, Lapidus RG, Cairo C, Li H. Gamma delta T cell therapy for cancer: it is good to be local. Front Immunol 2018;9:1305.
  86. Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G, Poccia F, Fournie JJ, Battistini L. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood 2004;104:1801-1807. https://doi.org/10.1182/blood-2004-01-0331
  87. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938-945. https://doi.org/10.1038/nm.3909
  88. Meraviglia S, Lo Presti E, Tosolini M, La Mendola C, Orlando V, Todaro M, Catalano V, Stassi G, Cicero G, Vieni S, et al. Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer. OncoImmunology 2017;6:e1347742.
  89. Kim JS, Kim YG, Park EJ, Kim B, Lee HK, Hong JT, Kim Y, Han SB. Cell-based immunotherapy for colorectal cancer with cytokine-induced killer cells. Immune Netw 2016;16:99-108. https://doi.org/10.4110/in.2016.16.2.99
  90. Park C, Kim TJ. Expansion and sub-classification of T cell-dependent antibody responses to encompass the role of innate-like T cells in antibody responses. Immune Netw 2018;18:e34.
  91. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013;123:2873-2892. https://doi.org/10.1172/JCI67428
  92. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, Sireci G, Fournie JJ, Dieli F. Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood 2011;118:129-138. https://doi.org/10.1182/blood-2011-01-331298
  93. Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell 2018;33:547-562. https://doi.org/10.1016/j.ccell.2018.03.012
  94. Xia A, Zhang Y, Xu J, Yin T, Lu XJ. T cell dysfunction in cancer immunity and immunotherapy. Front Immunol 2019;10:1719.
  95. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010;22:223-230. https://doi.org/10.1016/j.coi.2010.02.005
  96. Meraviglia S, Caccamo N, Guggino G, Tolomeo M, Siragusa S, Stassi G, Dieli F. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy. Curr Mol Med 2010;10:719-726. https://doi.org/10.2174/156652410793384150
  97. Zou C, Zhao P, Xiao Z, Han X, Fu F, Fu L. γδ T cells in cancer immunotherapy. Oncotarget 2017;8:8900-8909. https://doi.org/10.18632/oncotarget.13051
  98. Wu D, Wu P, Wu X, Ye J, Wang Z, Zhao S, Ni C, Hu G, Xu J, Han Y, et al. Ex vivo expanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer. OncoImmunology 2015;4:e992749.
  99. Siegers GM, Dhamko H, Wang XH, Mathieson AM, Kosaka Y, Felizardo TC, Medin JA, Tohda S, Schueler J, Fisch P, et al. Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 2011;13:753-764. https://doi.org/10.3109/14653249.2011.553595
  100. Goncalves-Sousa N, Ribot JC, deBarros A, Correia DV, Caramalho I, Silva-Santos B. Inhibition of murine gammadelta lymphocyte expansion and effector function by regulatory alphabeta T cells is cell-contact-dependent and sensitive to GITR modulation. Eur J Immunol 2010;40:61-70. https://doi.org/10.1002/eji.200939715
  101. Li W, Kubo S, Okuda A, Yamamoto H, Ueda H, Tanaka T, Nakamura H, Yamanishi H, Terada N, Okamura H. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother 2010;33:287-296. https://doi.org/10.1097/CJI.0b013e3181c80ffa
  102. Li W, Yamamoto H, Kubo S, Okamura H. Modulation of innate immunity by IL-18. J Reprod Immunol 2009;83:101-105. https://doi.org/10.1016/j.jri.2009.08.005
  103. Van Acker HH, Anguille S, Willemen Y, Van den Bergh JM, Berneman ZN, Lion E, Smits EL, Van Tendeloo VF. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J Hematol Oncol 2016;9:101.
  104. Wang X, Zhao X, Feng C, Weinstein A, Xia R, Wen W, Lv Q, Zuo S, Tang P, Yang X, et al. IL-36γ transforms the tumor microenvironment and promotes type 1 lymphocyte-mediated antitumor immune responses. Cancer Cell 2015;28:296-306. https://doi.org/10.1016/j.ccell.2015.07.014
  105. Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. J Immunol 2009;182:3423-3431. https://doi.org/10.4049/jimmunol.0803068
  106. Chen J, Niu H, He W, Ba D. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes. Int Arch Allergy Immunol 2001;125:256-263. https://doi.org/10.1159/000053824
  107. Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol 1995;154:3932-3940. https://doi.org/10.4049/jimmunol.154.8.3932
  108. Couzi L, Levaillant Y, Jamai A, Pitard V, Lassalle R, Martin K, Garrigue I, Hawchar O, Siberchicot F, Moore N, et al. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol 2010;21:181-188. https://doi.org/10.1681/ASN.2008101072
  109. Knight A, Arnouk H, Britt W, Gillespie GY, Cloud GA, Harkins L, Su Y, Lowdell MW, Lamb LS. CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells. PLoS One 2013;8:e68729.
  110. Knight A, Mackinnon S, Lowdell MW. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 2012;14:1110-1118. https://doi.org/10.3109/14653249.2012.700766
  111. Lanca T, Costa MF, Goncalves-Sousa N, Rei M, Grosso AR, Penido C, Silva-Santos B. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. J Immunol 2013;190:6673-6680. https://doi.org/10.4049/jimmunol.1300434
  112. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007;27:334-348. https://doi.org/10.1016/j.immuni.2007.05.020
  113. Mao Y, Yin S, Zhang J, Hu Y, Huang B, Cui L, Kang N, He W. A new effect of IL-4 on human γδ T cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells. Cell Mol Immunol 2016;13:217-228. https://doi.org/10.1038/cmi.2015.07